Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 15 (5) , 569-576
- https://doi.org/10.3109/02713689609000768
Abstract
Purpose. This study was designed to evaluate the intraocular distribution and metabolism of the antiviral nucleotide analogs cidofovir and cyclic l-[(S)-3-hydroxy-2-(phosphonomethoxy) propyljcytosine (HPMPC) in New Zealand white rabbits following intravitreal administration. Methods. Male rabbits received either 14C-cidofovir or 14C-cyclic HPMPC by intravitreal injection into both eyes (50 μg/eye, 11 μCi/eye). Two animals per group were sacrificed at 24, 48, 72 or 240 h post-dose. Ocular tissues, kidney and liver were oxidized to determine total radioactivity and metabolites were determined by HPLC. Results. At 24 h post-dose, total radioactivity was 9.96 and 5.18 μg-equiv/g for cidofovir and cyclic HPMPC, respectively, in vitreous and 20.9 and 3.54 μg-equiv/g, respectively, in retina. Although the initial vitreal clearance was 2-fold faster for the cyclic analog, the estimated terminal elimination half-lives in vitreous (42 hr) and in retina (66-77 hr) were similar for both drugs. By 240 h post-dose, radioactivity in all ocular tissues was approximately ten-fold higher for cidofovir. Radioactivity in vitreous at 240 h after intravitreal dosing with either drug contained cidofovir, cyclic HPMPC and cidofovir-phosphocholine. Conclusions. The long retinal half-life observed presumably reflects formation of phosphorylated cidofovir within retinal cells. Cidofovir achieved a ten-fold higher level of phosphorylated drug in retina than cyclic HPMPC. Therefore, intravitreal cidofovir may be expected to suppress progression of retinitis for a longer period than an equivalent intravitreal dose of cyclic HPMPC. The intravitreal half-life of cidofovir was 20-fold longer than that of ganciclovir in the same animal model.Keywords
This publication has 15 references indexed in Scilit:
- Phase I/II Study of Intravitreal Cidofovir for the Treatment of Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency SyndromeAmerican Journal of Ophthalmology, 1995
- Intravitreal Cidofovir (HPMPC) Treatment of Cytomegalovirus Retinitis in Patients with Acquired Immune Deficiency SyndromeOphthalmology, 1995
- Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruriaAntimicrobial Agents and Chemotherapy, 1995
- (S)-1-[3-Hydroxy-2-(Phosphonylmethoxy)propyl]cytosine (Cidofovir): Results of a Phase I/II Study of a Novel Antiviral Nucleotide AnalogueThe Journal of Infectious Diseases, 1995
- The cyclic congener of cidofovir has reduced nephrotoxicity in three speciesAntiviral Research, 1995
- 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivoAntimicrobial Agents and Chemotherapy, 1994
- Mortality in Patients with the Acquired Immunodeficiency Syndrome Treated with either Foscarnet or Ganciclovir for Cytomegalovirus RetinitisNew England Journal of Medicine, 1992
- The Causes of Death in Patients with Human Immunodeficiency Virus InfectionMedicine, 1991
- (S)-1-(3-Hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): A Potent Antiherpesvirus AgentPublished by Springer Nature ,1990
- Treatment of Cytomegalovirus Retinitis with Intravitreal GanciclovirOphthalmology, 1989